111in-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 2, 2009, Pages 163-173

  Cornelissen, Bart ^a   Kersemans, Veerle ^a   McLarty, Kristin ^a   Tran, Lara ^a   Reilly, Raymond M ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bispecific immunoconjugates; Breast cancer; Epidermal growth factor receptor; Indium 111; P27 Kip1; Trastuzumab

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; ANTIBODY CONJUGATE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1B ANTIBODY; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCYLGLYCYLPROLYLLYSYLLYSYLLYSYLARGINYLLYSYLVALYLGLYCYLTYROSYL GLYCYLCYSTEINYLGLYCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G GLYCYLGLYCYLPROLYLGLYCYLGLYCYLLYSYLARGINYLLYSYLVALYLGLYCYLTYROSYL GLYCYLCYSTEINYLGLYCINE EPIDERMAL GROWTH FACTOR PENTETATE INDIUM IN 111; IMMUNOGLOBULIN G GLYCYLGLYCYLPROLYLLYSYLLYSYLLYSYLARGINYLLYSYLVALYLGLYCYLTYROSYL GLYCYLCYSTEINYLGLYCINE PENTETATE INDIUM IN 111; IMMUNOGLOBULIN G GLYCYLGLYCYLPROLYLLYSYLLYSYLLYSYLARGINYLLYSYLVALYLGLYCYLTYROSYLGLYCYL CYSTEINYLGLYCINE EPIDERMAL GROWTH FACTOR PENTETATE INDIUM IN 111; MALEIMIDE; P27KIP1 ANTIBODY GLYCYLGLYCYLPROLYLLYSYLLYSYLLYSYLARGINYLLYSYLVALYLGLYCYLTYROSYLGLYCYL CYSTEINYLGLYCINE EPIDERMAL GROWTH FACTOR PENTETATE INDIUM IN 111; PEPTIDE; PROTEIN ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CDKN1B PROTEIN, HUMAN; INDIUM; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE;

ARTICLE; CANCER CELL; CELL LYSATE; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG RETENTION; HELA CELL; HUMAN; HUMAN CELL; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIMIAN VIRUS 40; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HELA CELLS; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 66249108561     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0553     Document Type: Article

References (33)

1. Reilly RM. The radiopharmaceutical science of monoclonal antibodies and peptides for imaging and targeted in situ radiotherapy of malignancies. In: Handbook of Biopharmaceutical Technology. Toronto, Ontario, Canada: Gad SC, ed. John Wiley&Sons, 2007; 987.
2. Misek DE, Imafuku Y, Hanash SM. Application of proteomic technologies to tumor analysis. Pharmacogenomics 2004; 5: 1129. (Pubitemid 40045253)
3. Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 2008; 83: 673.
4. Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 2008; 23: 3.
5. WAF-1/Cip-1. Eur J Nucl Med Mol Imaging 2007; 34: 368 (Pubitemid 46295344)
6. WAF-1/CIP-1. Bioconj Chem 2006; 17: 1280. (Pubitemid 44455338)
7. 111In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. Nucl Med Biol 2008; 35: 101. (Pubitemid 350302045)
8. Hu M, Chen P, Wang J, et al. Site-specific conjugation of HIV- 1 tat peptides to IgG: A potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. Eur J Nucl Med Mol Imaging 2006; 33: 301.
9. 123I]- labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nucl Med Biol 2007: 34: 37. (Pubitemid 46038158)
10. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001; 12 (Suppl 1) : S35. (Pubitemid 32750583)
11. DuManoir J, Francia G, Man S, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006; 12: 904. (Pubitemid 43259873)
12. 111In]-IGF-1 (E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 2008; 35: 645.
13. Fraker PJ, Speck JC, Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1, 3, 4, 6-tetrachloro- 3a, 6a- diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849. (Pubitemid 8305904)
14. Reilly RM, Kiarash R, Cameron R et al. Indium-111-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000; 41: 429. (Pubitemid 30133961)
15. 111In for imaging human breast cancer. J Nucl Med 2000; 41: 903. (Pubitemid 30266037)
16. Buhler P Wolf P, Gierschner D, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induced T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 2008; 57: 43. (Pubitemid 350043647)
17. Renard, I, Mezzanzanica D, Canevari S. Anti-CD3= anti-epidermal growth factor receptor-bispecific antibody retargeting of lymphocytes against human neoplastic keratinocytes in an autologous organotypic culture model. Am J Pathol 2002; 160: 113. (Pubitemid 34052272)
18. Cao Y, Lam L. Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev 2003; 55: 171. (Pubitemid 36135915)
19. Tian X, Amirkhanov, NV, Aruva MR, et al. External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumortargeted radionuclide-PNA-peptide chimeras. Ann NY Acad Sci 2005; 1059: 106. (Pubitemid 43211616)
20. Capello A, Krenning EP, Bernard BF, et al. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med 2004: 45: 1716. (Pubitemid 47618481)
21. Wang J, Chen P, Su ZF, et al. Amplified delivery of indium- 111 to EGFR-positive human breast cancer cells. Nucl Med Biol 2001; 28: 895. (Pubitemid 33050021)
22. Cawley DB, Herschman HR, Gilliland DG, et al. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell 1980; 22: 563. (Pubitemid 11199913)
23. Andersson A, Holmberg A, Carlsson J, et al. Binding of epidermal growth factor-dextran conjugates to cultured glioma cells. Int J Cancer 1991; 47: 439.
24. Lee H, Hu M, Reilly RM, et al. Apoptotic epidermal growth factor (EGF) -conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy. Mol Pharmaceut 2007; 4: 769. (Pubitemid 350004277)
25. Chen P, Wang J, Hope K, et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med 2006; 47: 827. (Pubitemid 46768447)
26. 111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS) : An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007; 48: 1357. (Pubitemid 47242802)
27. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802. (Pubitemid 32842685)
28. 111In-DTPA-hEGF. Nucl Med Biol 2007; 34: 887. (Pubitemid 350061165)
29. HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37: 255. (Pubitemid 23300507)
30. Hendriks BS, Opresko LK, Wiley HS, et al. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis. J Biol Chem 2003; 278: 23343.
31. Kip1 down regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64: 3981. (Pubitemid 38697313)
32. Lane HA, Motoyama AB, Beuvink I, et al. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Annal Oncol 2001; 12: S21. (Pubitemid 32750580)
33. Kip1 in anti-HER2 antibodyinduced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 2003; 278: 23441. (Pubitemid 36830161)